Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

Clinical trial NCT01482962 · COMPLETED

Trial details

NCT number: NCT01482962
Sponsor: Millennium Pharmaceuticals, Inc.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Relapsed Peripheral T-Cell Lymphoma Refractory Peripheral T-Cell Lymphoma

Start date: 2012-06-11
Primary completion: 2015-06-30
Enrollment: 271

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.